studies

mUC - L1 - PDL1 positive, immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDANUBE (D vs C - PDL1>25%), 2020 0.89 [0.71; 1.11] DANUBE (DT vs C - PDL1>25%), 2020 0.74 [0.59; 0.93] 0.81[0.68; 0.97]DANUBE (D vs C - PDL1>25%), 2020, DANUBE (DT vs C - PDL1>25%), 2020222%828moderatenot evaluable progression or deaths (PFS)detailed resultsDANUBE (D vs C - PDL1>25%), 2020 1.24 [0.74; 2.08] DANUBE (DT vs C - PDL1>25%), 2020 1.02 [0.62; 1.68] 1.12[0.78; 1.61]DANUBE (D vs C - PDL1>25%), 2020, DANUBE (DT vs C - PDL1>25%), 202020%828moderatenot evaluable DORdetailed resultsDANUBE (D vs C - PDL1>25%), 2020 0.27 [0.13; 0.57] DANUBE (DT vs C - PDL1>25%), 2020 0.38 [0.19; 0.75] 0.33[0.20; 0.54]DANUBE (D vs C - PDL1>25%), 2020, DANUBE (DT vs C - PDL1>25%), 202020%354moderatenot evaluable objective responses (ORR)detailed resultsDANUBE (D vs C - PDL1>25%), 2020 0.41 [0.27; 0.62] DANUBE (DT vs C - PDL1>25%), 2020 0.94 [0.64; 1.39] 0.62[0.28; 1.41]DANUBE (D vs C - PDL1>25%), 2020, DANUBE (DT vs C - PDL1>25%), 2020288%828moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-02 17:52 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 157 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743